Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fitusiran Delay Dents Sanofi’s Hemophilia Challenge

Company Still Aiming For Universal Therapy

Executive Summary

New data show fitusiran’s promise across hemophilia A and B, but a switch to a lower dose prompted by safety concerns will delay its filing until 2024.

You may also be interested in...



Sanofi Continues Hunt For External Innovation With Skyhawk Deal

Deal Snapshot: A lot of the French drug maker’s interest has focused on biologics, but the Skyhawk deal shows it has maintained a keen interest in innovative small molecules as well.

As BioMarin Stumbles, Sanofi Gets Breakthrough Status For Hemlibra Challenger

Sanofi and its partner Sobi believe they have the future “Factor VIII of choice” t could also challenge the dominance of Roche’s Hemlibra.

Sanofi Looks To Dominate $5bn Hemophilia A Factor Market After Trial Success

Phase III success for efanesoctocog alfa sets up a filing in the near future, and a chance to seize market share from existing Factor VIII products, as well as Roche’s Hemlibra.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145577

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel